EMA approves eight meds for market
The EMAs human medicines committee (CHMP) has recommended eight medicines for approval in its last meeting in London, two thereof orphan medicines. Three got conditional marketing authorisation.
Genfit set to raise $100m in Nasdaq IPO
French Genfit SA has registered at SEC for an Nasdaq IPO of ADS in conjunction with private placements in Europe and the US.
Targeting NFkappaB protects tendons from injury
Researchers from the UK and the US have prevented tendon injury and degeneration by simply blocking a key signalling pathway in inflammation.
Anaveon bags CHF35m series A financing
University Zurich spin-off Anaveon AG announced it will proceeds from its financing round to push development of its preclinical IL-2-receptor agonist.
AMR network CARB-X expands reach
The global antibacterial innovation network CARB-X has expanded its reach by adding six new life-science organisations to its fight against antimicrobial resistance (AMR).
Roche swallows Spark Therapeutics in $4.3bn deal
Swiss pharma giant Roche has complemented its drug pipeline in the lucrative hemophilia A market by taking over hemophilia A gene therapy developer Spark Therapeutics for US$4.3bn.
How salt triggers allergy
Sodium chloride can promote immune responses that have been linked to atopic dermatitis. Researchers have now unraveled the mechanistic details between salt intake and activation of T cells.
Calypso Biotech cash in 20M Series A financing
Dutch autoimmunity specialist Calypso Biotech BV has raised 20m in a Series A financing co-led by Gilde Healthcare and Inkef Capital and co-financed by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and the companys seed investor M Ventures.
Evotec and HZI join forces in antibiotics discovery
Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel resistance-breaking antibiotics against Gram-negative bugs.
First immunotolerant allogenic cell transplants revealed
Researchers for the first time have found a way to prevent immune rejection of allogenic iPSC-derived cell and tissue transplants.